The importance of venetoclax in treating CLL

Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from St James's University Hospital Leeds, Leeds, UK, provides us an insight into the clinical effectiveness of venetoclax in treating chronic lymphocytic leukemia (CLL) and how it should be integrated into novel drug combinations to hopefully achieve a synergistic effect. He also notes that several drug combinations including venetoclax as one of the drugs have shown successful results and have proceeded forward into Phase III trials and that the future of therapy will be focused on treating patients effectively up-front to avoid treating refractory disease. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.